Imugene Limited

ASX (AUD): Imugene Limited (IMU)

Last Price

0.476

Today's Change

+0.034 (7.69%)

Day's Change

0.408 - 0.476

Trading Volume

303,265

Overview

Market Cap

Shares Outstanding

Avg Volume

Avg Price (50 Days)

Avg Price (200 Days)

PE Ratio

EPS

Earnings Announcement

Previous Close

Open

Day's Range

Year Range

Trading Volume

Price Change Highlight

1 Day Change

5 Day Change

1 Month Change

3 Month Change

6 Month Change

Ytd Change

1 Year Change

3 Year Change

5 Year Change

10 Year Change

Max Change

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment